Printer Friendly

The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape.

LYON, France -- announces that a new market research report related to the worldwide pharmaceutical market is available in its catalogue.

The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape

To order that report:

For more information, contact Nicolas by email , or by phone +33 4 37 65 17 03.



The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales.

The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.

Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance.

In addition, a number of new drug classes such as dihydrofolate reductase inhibitors (DHFR) are under evaluation which are effective in multi drug resistant organisms.

This report examines each of the antibacterial classes in turn, assessing the market potential and application in hospital and community-acquired infections.

The following product classes are analyzed in this report: aminoglycosides, carbapenems, cephalosporins, dihydrofolate, reductase inhibitors, glycopeptides, ketolides, lipopeptides, macrolides, penicillins, oxazolidinones, pleuromutulins, quinolones.

The report assesses the overall antibacterial market, key classes and the drivers and resistors influencing their prescription.

The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position.

The overview of the current market is given in terms of segmentation and by leading players and their products and analyzes market trends.

The report also examines promising pipeline products and their potential impact on the prescription of current and new antibacterial agents and the future of the antibacterial market.

Key Features of this report:

Overview of the antibacterial market, including the main infectious agents, therapeutic drug classes and key players.

In-depth analysis of different classes of antibacterial agents, including leading antibacterial agents and a summary of leading brands within each class.

Comprehensive facts and figures for the antibacterial market, including main players and drug class break-downs.

Future trends in the antibacterial marketplace, driven by drug resistance and patient demographics.

Outlook for the antibacterial market, including the emergence of novel therapies and the impact of generics.

Table of content



2.1 Group A Streptococcus (GAS)

2.2 Group B Streptococcus (GBS)

2.3 Streptococcus pneumoniae

2.4 Haemophilus Influenzae

2.5 Neisseria Meningitidis

2.6 Methicillin Resistant Staphylococcus Aurens (MRSA)


3.1 Group A Streptococcus (GAS) Patient Statistics

3.2 Group B Streptococcus (GBS) Patient Statistics

3.3 Streptococcus pneumoniae Patient Statistics

3.4 Haemophilus Influenzae Patient Statistics

3.5 Neisseria Meningitidis Patient Statistics

3.6 MRSA Patient Statistics


4.1 Drug Resistance

4.2 New Treatments


4.4 Vaccines

4.5 Potential for Clinical Success

4.6 Indirect Cost Associated with Infectious Diseases


5.1 Over-prescription

5.2 Antibiotic Resistance Leading to Short Antibacterial Drug Lifecycles

5.3 Acute Use of Antibiotics

5.4 Generics

5.5 Curative Therapies and Vaccines


6.1 The Global Anti-infective Market

6.2 Market Segments

6.3 Global Antibacterial Market

6.3.1 Cephalosporin Antibiotics

6.3.2 Macrolide Antibiotics

6.3.3 Penicillin Antibiotics

6.3.4 Quinolone Antibiotics

6.3.5 Other Antibiotics

6.4 The Major Players

6.4.1 Antibacterial Major Players in 2006

6.4.2 Antibacterial Major Players in 2012

6.5 Market Trends

6.5.1 Antibacterial Agents by 2012


7.1 Aminoglycosides

7.2 Carbapenems

7.3 Cephalosporins

7.4 Glycopeptide

7.5 Ketolide

7.6 Lipopeptide

7.7 Macrolides

7.8 Penicillins

7.9 Oxazolidinones

7.10 Pleuromutilins

7.11 Quinolone


8.1 Aminogylcoside Antibiotics

8.1.1 Tygacil (Wyeth)

8.1.2 Leading Aminoglycoside Sales Forecasts

8.2 Carbapenem Antibiotics

8.2.1 Finibax (Shionogi/ Johnson & Johnson/[Peninsula])

8.2.2 Merrem/Meronem (AstraZeneca/Sumitomo Pharmaceuticals)

8.2.3 Primaxin/Tieman (Merck & Co.)

8.2.4 Leading Carbapenem Sales Forecasts

8.3 Cephalosporins

8.3.1 Ceftin/Zinnat (GlaxoSmithKline)

8.3.2 Flumarin (Shionogi)

8.3.3 Omnicef/Cefzon (Abbott Laboratories/Astellas)

8.3.4 Rocephin (Roche)

8.3.5 Leading Cephalosporin Sales Forecasts

8.4 Glycopeptide Antibiotics

8.4.1 Vancomycin (Shionogi/ViroPharm/[Eli Lilly])

8.4.2 Targocid (Sanofi-Aventis/Astellas)

8.4.3 Leading Glycopeptide Sales Forecasts

8.5 Ketolide Antibiotics

8.5.1 Ketek (Sanofi-Aventis/Astellas)

8.5.2 Leading Ketolide Sales Forecasts

8.6 Lipopeptide Antibiotics

8.6.1 Cubicin (Cubist Pharmaceuticals/Novartis)

8.6.2 Leading Lipopeptide Sales Forecasts

8.7 Macrolide Antibiotics

8.7.1 Biaxin/Biaxin XL (Abbott Laboratories)

8.7.2 Zithromax/Zmax (Pfizer)

8.7.3 Macrolide Sales Forecasts

8.8 Oxazolidinone Antibiotics

8.8.1 Zyvox/Zyvoxid (Pfizer)

8.8.2 Leading Oxazolidinone Sales Forecasts

8.9 Penicillin Antibiotics

8.9.1 Augmentin (GlaxoSmithKline)

8.9.2 Zosyn/Tazocin (Wyeth)

8.9.3 Leading Penicillin Sales Forecasts

8.10 Quinolone Antibiotics

8.10.1 Avelox/Avalox (Astellas/Bayer/Schering-Plough)

8.10.2 Levaquin/Cravit and Floxin/Tarivid (Johnson & Johnson/Daiichi Sankyo/Santen Pharmaceuticals)

8.10.3 Cipro/Ciprobay/Ciproxin (Bayer/Schering-Plough)

8.10.4 Leading Quinolone Sales Forecasts

8.11 Pleuromutilin Antibiotics

8.11.1 Altabax/Altargo (GlaxoSmithKline)

8.11.2 Leading Pleuromutilin Sales Forecasts

8.12 Other Antibiotics

8.13 Global Antibacterial Sales Forecasts


9.1 Carbapenem Antibiotics

9.1.1 Faropenem Medoxomil (Replidyne)

9.1.2 PF-3,709,270 (Pfizer)

9.1.3 R1558 (Roche/Daiichi-Sankyo)

9.2 Cephalosporin Antibiotics

9.2.1 Ceftobiprole (J&J/[Basilea])

9.2.2 Ceftaroline (Cerexa/[Takeda])

9.3 Dihydrofolate Reductase Inhibitor Antibiotics

9.3.1 Iclaprim (Arpida/[Roche])

9.3.2 AR-709 (Arpida)

9.4 Glycopeptide Antibiotics

9.4.1 Oritavancin (Targanta/[InterMune])

9.4.2 Telavancin (Astellas/Theravance)

9.4.3 Zeven (Pfizer/[Vicuron Pharmaceuticals])

9.5 Ketolide Antibiotics

9.5.1 Cethromycin (Advanced Life Sciences/[Abbott])

9.6 Macrolides

9.6.1 S-013420 (Shionogi/[Enanta Pharmaceuticals])

9.6.2 Quinolone

9.6.3 ABT-492 (Abbott/[Wakunga Pharmaceuticals])

9.6.4 DX-619 (Daiichi-Sankyo)

9.6.5 Gracevit (Daiichi-Sankyo)

9.6.6 Garenoxacin (Schering-Plough/[Toyama])

9.6.7 Olamufloxacin (Abbott)

9.7 Other Antibiotics

9.7.1 Aurograb (Novartis/[NeuTec])

9.7.2 Tifacogin (Novartis/[Chiron])

9.7.3 REP8839 (Replidyne)

9.8 Future Global Antibacterial Sales Forecasts


10.1 Advanced Life Sciences

10.2 Arpida Ltd

10.3 Basilea Pharmaceutica AG

10.4 Cerexa Inc.

10.5 Cubist Pharmaceuticals, Inc.

10.6 Targanta Therapeutics Corp.

10.7 Theravance

APPENDIX 3: Acronyms


Table 2.1 Infectious Disease Leading Worldwide Health Burden

Table 4.1 Potential for Clinical Success

Table 6.1 Historical Sales of Leading Antibiotics 2001-2005

Table 7.1 Different Classes of Antibacterial Agents

Table 8.1 Common Bacterial Infections

Table 8.2 Sales Forecasts of Leading Aminoglycosides US$mn 2005A - 2012E

Table 8.3 Sales Forecasts of Leading Carbapenems US$2005-2012E

Table 8.4 Approved Cephalosporin Antibiotics

Table 8.5 Sales Forecasts of Cephalosporins US$mn 2005-2012E

Table 8.6 Sales Forecasts of Leading Glycopeptides US$mn 2005A - 2012E

Table 8.7 Sales Forecasts of Ketolide Antibiotics US$mn 2005 - 2012E

Table 8.8 Clinical Efficacy of Cubicin Versus Comparator on Pathogens

Table 8.9 Sales Forecasts of Leading Lipopeptides US$mn 2005A - 2012E

Table 8.10 Sales Forecasts of Leading Macrolides US$m 2005A - 2012E

Table 8.11 Sales Forecasts of Leading Oxazolidinones US$m 2005A - 2012E

Table 8.12 Approved Penicillins

Table 8.13 Sales Forecasts of Leading Penicillins US$m 2005A - 2012E

Table 8.14 Approved Quinolone Antibiotics

Table 8.15 Sales Forecasts of Leading Quinolones US$m 2005A - 2012E

Table 8.16 Sales Forecasts of Leading Pleuromutilins US$m 2005A - 2012E

Table 8.17 Sales Summary of Leading Antibacterial Agents (US$m) 2005 - 2012E

Table 9.1 Antibiotics in Clinical Development

Table 9.2 DX-619 Potent Quinolone in Vitro Against Gram Positive Pathogens

Table 9.3: Sales Summary of New Antibacterial Agents (US$m) 2005 - 2012E


Figure 3.1 MRSA Among ICU Patients in the US, 1995-2004

Figure 6.1 Global Anti-Infective Market 2006

Figure 6.2 Global Anti-Infective Market 2015

Figure 6.3 Antibacterial Sales Split - Drug Class Split 2006

Figure 6.4 Cephalosporin Antibiotics - Leading Drugs 2006

Figure 6.5 Macrolide Antibiotics - Leading Drugs 2006

Figure 6.6 Penicillin Antibiotics - Leading Drugs 2006

Figure 6.7 Quinolone Antibiotics - Leading Drugs 2006

Figure 6.8 Other Antibiotics - Leading Drugs 2006

Figure 6.9 The Major Players 2006

Figure 6.10 The Major Players 2012

Figure 6.11 Antibacterial Agents - Drug Class Split 2012

Figure 7.1 Site of Action of Leading Antibacterial Agents

Figure 9.1 Number of Drugs in Development to Treat Infectious Diseases

Figure 9.2 Schematic of Drug-resistant Pathogens and Market Opportunities

Figure 9.3 DX-619 Effective in Severe Infection Models Potent Quinolone in Vitro Against Gram Positive Pathogens

Figure 9.4 DC-159a Effective in Severe RTI

More market research reports? Go to
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 20, 2007
Previous Article:The Mobile Operators Celcom, and Maxis Are Covered inside the Latest Q4 Mobile Forecast for Malaysia for the Years 2007 - 2010.
Next Article:The Airport Construction Market in Poland: Development Forecasts for 2008-2013.

Related Articles
NAFTA polyurethane production shifting.
Cost Management in Plastics Processing.
Small commercial is redefined: insurers who open up eligibility, thresholds for the small commercial market allow themselves--and their partners--to...
On solid ground: the high stakes involved in competing in a global economy are driving insurers to take a holistic view of data used in enterprise...
Global playbook: globalization and integration are helping insurers achieve business goals.
Carbon black demand to increase worldwide by 4.2% through 2011.
New product development key to success of pigment producers.
Paint and coatings: what will be coloring the market in 2007?

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters